Shenzhen Chipscreen Biosciences, Ltd.

Tsinghua University

Chipscreen Biosciences, Ltd.

Shenzhen Chipscreen Biosciences Co., Ltd.

Zhiqiang Ning

You Zhou

Zhibin Li

Song Shan

Xian-Ping Lu

Tuo Deng

Leming Shi

Jindi Yu

Boyu Li

Weiming Hu

Chenzhong Liao

Zhende Liu

Baoshun Ma

Aihua Xie

Desi Pan

Yanan Wang

Xianping Lu

Xianghui Wang

Lijun Xin

Qianjiao Yang

Jiangfei Zhu

Xiangheng Liu

Shigang Wang

Yidi Kong

An application of a compound having general formula (I) as JAK3 and/or JAK1 kinase and a preparation method for the compound.

Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound

Isolated compounds of formula I: and stereoisomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof are described, as well as processes for production, and methods of use of these compounds and compositions thereof for the treatment of diseases associated with abnormal protein kinase activities and/or abnormal histone deacetylase activities including, for example, inflammatory diseases, autoimmune diseases, cancer, neurological and neurodegenerative diseases, cardiovascular diseases, metabolic disease, allergies and asthma and/or hormone-related diseases.

Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors

The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis. 

Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity

Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R, R, R, R, R, X, Alk, Alk, Ar, and Arare as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists. 

Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

The present invention is related to the preparation and pharmaceutical use of novel benzamide derivatives as defined in the specification of formula (I) as histone deacetylase inhibitors (HDACI), their preparations and the methods of using these compounds or their pharmaceutically acceptable salt in the treatment of cell proliferative diseases, e.g. cancer and psoriasis 

Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity

Disclosed are the preparation and pharmaceutical use of novel noncyclic 1,3-dicarbonyl compounds of formula I, wherein ring A, ring B, R, R, R, R, R, X, Y, Z, Q, Ar and n are as defined in the specification. These compounds, as peroxisome proliferator-activated receptor (PPAR) dual agonists for both RXR/PPARgamma and RXR/PPARalpha heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders 

Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity

Growing community of inventors

Guangdong, China

Zhiqiang Ning